GlassScriptPhysician profile
Shruti Polu
NPI 1982088621
$5,181.75
in general payments reported to CMS, 2019-2025
26 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $320 · 2021: $1,056 · 2022: $1,108 · 2023: $967 · 2024: $934 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,009.28 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $857.98 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $519.10 | 2020-2024 | Farxiga |
| Medtronic, INC. | $414.97 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $404.36 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $374.94 | 2020-2025 | |
| Amgen INC. | $325.78 | 2020-2025 | Evenity, Prolia, Prolia |
| Cequr Corporation | $206.79 | 2021-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.37 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $151.24 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $134.80 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $131.96 | 2021-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $109.53 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $79.14 | 2025 | Omnipod |
| Mannkind Corporation | $43.93 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.56 | 2024 | |
| Intuity Medical INC | $31.37 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Beta Bionics, INC. | $27.68 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $25.76 | 2022-2023 | Tirosint, Licart |
| Zealand Pharma US, INC. | $20.54 | 2021 | |
| Recordati_rare_diseases_inc. | $17.19 | 2025 | Isturisa |
| Radius Health, INC. | $17.00 | 2025 | Tymlos |
| Halozyme INC | $16.99 | 2023 | |
| Kyowa Kirin, INC. | $15.34 | 2025 | |
| Neurocrine Biosciences, INC. | $14.13 | 2025 | |
| Chiesi USA, INC. | $14.02 | 2024 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Polu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.